GlassScriptPhysician profile
Lisa A Davis
NPI 1285648808
$7,750.62
in general payments reported to CMS, 2019-2025
42 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,073 · 2020: $744 · 2021: $1,255 · 2022: $1,128 · 2023: $1,225 · 2024: $1,057 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,550.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,907.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $819.42 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $811.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $556.40 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $429.88 | 2019-2025 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $405.00 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $326.24 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $254.55 | 2021-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $239.41 | 2019-2023 | Spravato, Xarelto |
| Pfizer INC. | $235.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $229.05 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $162.39 | 2025 | |
| Astellas Pharma US INC | $142.37 | 2019-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $132.99 | 2023-2025 | Gemtesa |
| Nevro Corp. | $113.19 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.